A registered PHASE1, PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Unknown. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 1, Phase 2
- Study design
- RANDOMIZED · PARALLEL · TREATMENT · NONE
- Evidence population
- Human clinical study registration
- Participants
- 30
- Population
- ALL · 50 Years
- Duration
- 2018-09-11 to 2020-06-01
- Intervention
- Aflibercept Injection
- Comparator
- Not reported
- Outcomes measured
- Incidence and severity of ocular and non ocular adverse events through to week 12 of intensive IAI therapy — Baseline t…; Mean change in BCVA from baseline to week 12 — Baseline to week 12; Mean change in BCVA from baseline to week 52 — Baseline to week 52; Number of patients who are able to maintain a dry macula with IAI intervals extending beyond q4w. — Baseline to week 52; Mean number of injections to achieve fluid-free status and at week 12 and week 52 — Baseline to week 52; Incidence and severity of adverse events through week 52 — Baseline to week 52; Polyp size reduction or closure - compare polyp and lesion area size to baseline on Heidelberg Eye Explorer software (T…; Mean change to area of flow within neovascular network on OCT-angiography (OCTA) — Baseline to week 12; Mean change to area of flow within neovascular network on OCT-angiography (OCTA) — Baseline to week 52; Mean change in lesion — Baseline to week 12; Mean change in lesion — Baseline to week 52; Number of patients whose fovea remain dry upon extending to q4w IAI at week 52 — Baseline to week 52; Number of patients whose subfoveal fluid is resolved or with no further increase in extrafoveal fluid — Baseline to wee…
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 60% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 60%Source terminology contains a controlled topic term. Source terminology supplies ageing or longevity context.
Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.